Morningstar

Atara Biotherapeutics Inc ATRA

Morningstar Rating

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Sep 6, 2024 8:01pm
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Sep 4, 2024 8:01pm
Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Business Wire Sep 3, 2024 8:16pm
Sidoti Events, LLC's Virtual August Micro-Cap Conference

Accesswire Aug 13, 2024 1:30pm
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Business Wire Aug 12, 2024 9:00pm
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire Aug 7, 2024 8:01pm
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Business Wire Jul 17, 2024 1:00pm
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

GlobeNewswire Jul 17, 2024 11:00am
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Jul 5, 2024 8:01pm
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Business Wire Jul 3, 2024 11:57pm
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application

Global News Select Feb 29, 2024 2:35pm
Atara Biotherapeutics to Submit New FDA Biologics License Application in 2Q

Global News Select Sep 19, 2023 8:35pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.